
Nicole Longo Nicole is senior director of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Recent Posts
CMS guidance on IRA price setting process doubles down on bad policy

As part of the implementation of the Inflation Reduction Act (IRA), the Centers for Medicare & Medicaid Services (CMS) issued draft guidance on the process for setting the price of medicines. The...
Read More
A guide to MedPAC’s Part B vote today

Today, the Medicare Payment Advisory Commission (MedPAC), an independent congressional agency that advises Congress on issues related to the Medicare program, will vote on draft recommendations...
Read More
MedPAC proposal threatens access to medicines in Part B

Next week, the Medicare Payment Advisory Commission (MedPAC) will vote on a number of policy proposals for changing Medicare Part B. One of the proposals would recommend that Congress adjust the...
Read More
How Part B’s ASP system helps control costs for the government and seniors

Between Congress, the Medicare Payment Advisory Commission (MedPAC) and the Center for Medicare & Medicaid Innovation (CMMI), there have been a number of policy proposals of late that would change...
Read More
Medicare Part B spending in four points

It’s that time of year again when the president releases his budget and questions arise about the solvency of the Medicare trust fund and Medicare spending more generally. Too often, critics point to...
Read More
Why Congress should prioritize fixing the 340B program

Nearly all Americans nationwide agree: Lowering out-of-pocket costs for health care should be a top priority for policymakers. Luckily, there are commonsense policies Congress could implement to...
Read More
WTAS: Inflation Reduction Act already impacting R&D decisions

The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions. Whether you are looking at estimates...
Read More
340B program continues to drive shift in care to more expensive hospital settings

Yet another study highlights the unintended consequences of the 340B program, which is increasing costs for patients and the health care system as a whole. In this case, the Berkeley Research Group...
Read More
The 340B program is interfering with the U.S. biosimilars market and impacting patient costs

Research has shown that 340B hospitals are more likely to prescribe more expensive medicines and significantly mark up the price of medicines. For example, 340B hospitals received nearly five times...
Read More
Medicare Part D open enrollment and what recent changes mean for beneficiaries

It’s that time of year again: Medicare open enrollment! Seniors and people with disabilities who are newly eligible for Medicare, as well as current Medicare beneficiaries, can select or update their...
Read More